Pharma
-
OKYO Pharma: An Emerging Biopharma With Game Changing Treatments In Ophthalmology
OKYO Pharma's main drug has already surpassed Phase 1 and reached Phase 2. OK-101 is catering to niches within the…
Read More » -
NanoViricides Gets Big Funding Boost From CEO Dr. Anil Diwan Prior To IND Application
Based in Connecticut, NanoViricides is a growth stage firm that’s at superior levels of trials with respect to a number…
Read More » -
NanoViricides: Grab This Biopharma Player While Inexpensive
Investment timing is among the most important ideas associated to the world of stock market investing. While its software is…
Read More » -
NanoKnife FDA Approval Is The Highlight Of An Otherwise Tepid AngioDynamics Quarter
Latham, New York: AngioDynamics, Inc. (NASDAQ:ANGO) is a number one supplier of modern, minimally invasive medical units utilized by skilled…
Read More » -
Lexicon’s Volatility Could Be Your Friend After The Zynquista Rejection
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is an organization identified for locating novel drug targets and drug candidates developed from state-of-the-art medicinal…
Read More » -
Amphastar Had A Good 2018 With Multiple ANDA Approvals
Rancho Cucamonga, CA: Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) is a specialty pharmaceutical firm that focuses totally on creating, manufacturing, advertising, and…
Read More » -
Aerie Pharmaceuticals Delivers Mixed Result; Focus On International Expansion
Durhan, NC: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a scientific stage pharmaceutical firm targeted on offering therapies for the therapy of eye-related…
Read More » -
Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and Japan
With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large…
Read More » -
Amgen pays $50M for Molecular Partners’ preclinical Anti-cancer
Amgen is paying Molecular Partners $50 million (€44 million) upfront for world rights to preclinical anti-cancer immune cell activator MP0310.…
Read More » -
Orchard Therapeutics commits to gene therapies production facility with plans to hire 100 workers
Orchard Therapeutics mentioned it supposed to use a few of the proceeds of an IPO to construct a producing facility…
Read More »
